Status:
RECRUITING
Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)
Lead Sponsor:
Lund University Hospital
Conditions:
Metastatic Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure. The main aim is to develop and validate prognostic...
Eligibility Criteria
Inclusion
- Patients with pathologically confirmed advanced breast cancer (ABC), including locally advanced inoperable disease and stage IV disease.
- Age \> 18 years.
- Performance status according to Eastern Cooperative Oncology Group (ECOG) ≤ 2.
- ABC must be radiologically or clinically assessable, by means of at least one of the following techniques: clinical examination, computerized tomography (CT-scan), magnetic resonance imaging (MRI), bone scintigraphy or positron emission tomography (PET).
- Patients must have a radiological evaluation done maximum 6 weeks prior to inclusion.
- Signed informed consent according to ICH/GCP, and national/local regulations.
Exclusion
- Untreated psychiatric disorders that will impair the patient's ability to comply with study treatment or protocol.
Key Trial Info
Start Date :
January 21 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2030
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03758976
Start Date
January 21 2019
End Date
December 1 2030
Last Update
September 16 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Lund University Hospital
Lund, Sweden, 221 85
2
Lund University Hospital
Lund, Sweden, 221 85